{
    "clinical_study": {
        "@rank": "43499", 
        "arm_group": [
            {
                "arm_group_label": "Formoterol + fluticasone propionate 100 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Formoterol 12 mcg + fluticasone propionate 100 mcg"
            }, 
            {
                "arm_group_label": "Formoterol + fluticasone propionate 250 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Formoterol 12 mcg + fluticasone propionate 250 mcg"
            }, 
            {
                "arm_group_label": "Formoterol + fluticasone propionate 500 mcg", 
                "arm_group_type": "Experimental", 
                "description": "Formoterol 12 mcg + fluticasone propionate 500 mcg"
            }, 
            {
                "arm_group_label": "Fluticasone propionate 100 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo + fluticasone propionate 100 mcg"
            }, 
            {
                "arm_group_label": "Fluticasone propionate 250 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo + fluticasone propionate 250 mcg"
            }, 
            {
                "arm_group_label": "Fluticasone propionate 500 mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Placebo + fluticasone propionate 500 mcg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether the risk of serious asthma-related events\n      (asthma-related hospitalizations, asthma related intubations, and asthma related deaths) in\n      adolescents and adults (12 years of age and older) taking inhaled formoterol\n      fumarate/fluticasone propionate combination is the same as those taking inhaled fluticasone\n      propionate alone."
        }, 
        "brief_title": "Study of Safety of Foradil in Patients With Persistent Asthma", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Persistent Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "This is a 26 week, double blind, randomized, active-controlled safety study of Foradil in\n      free combination with inhaled corticosteroid versus an inhaled corticosteroid alone in\n      adults and adolescent patients with persistent asthma. The primary objective of the study is\n      to demonstrate that the addition of formoterol fumarate to fluticasone propionate is\n      non-inferior to fluticasone propionate alone in terms of the risk of composite serious\n      asthma related events (asthma-related hospitalization, asthma-related intubation, and\n      asthma-related death). The individual components of the composite primary endpoint (i.e.,\n      asthma-related hospitalization, asthma-related intubation and asthma-related death) will be\n      assessed as a secondary safety endpoints.\n\n      The efficacy assessment is the secondary objective."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent, and assent if applicable, must be obtained before any\n             assessment is performed.\n\n          2. Male or female patients 12 years of age and older\n\n          3. Confirmed diagnosis of persistent asthma, as defined by national and international\n             asthma guidelines (e.g., GINA; NIH; etc.) for at least 1 year prior to study\n             enrollment.\n\n          4. PEF\u226550% of predicted normal value.\n\n          5. Current and appropriate use of one of the treatments listed in the protocol for\n             asthma.\n\n          6. Recent asthma exacerbation between 30 days and 12 months prior to randomization that\n             either:\n\n               -  required treatment with systemic corticosteroids (tablets, suspension, or\n                  injection) or\n\n               -  required hospitalization (defined as an inpatient stay or >24-hour stay in an\n                  observation area in an emergency room or other equivalent facility)\n\n        Exclusion Criteria:\n\n          1. History of life-threatening asthma episode that required intubation and/or was\n             associated with hypercapnia requiring non-invasive ventilatory support.\n\n          2. Current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease,\n             allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia,\n             or other respiratory abnormalities other than asthma.\n\n          3. Current evidence of, or past physician assessment of, chronic bronchitis, emphysema,\n             or chronic obstructive pulmonary disease.\n\n          4. History of smoking \u2265 10 pack years.\n\n          5. Exercise induced asthma (as the only asthma-related diagnosis) not requiring daily\n             asthma control medicine.\n\n          6. Suspected or documented bacterial or viral infection of the upper or lower\n             respiratory tract, sinus or middle ear that is not resolved at randomization.\n\n          7. Worsening/Unstable asthma within 7 days prior to randomization.\n\n          8. Any asthma exacerbation requiring systemic corticosteroids within 30 days of\n             randomization or more than 4 separate exacerbations in the 12 months preceding\n             randomization.\n\n          9. Two or more hospitalizations for greater than 24 hours duration for treatment of\n             asthma in the 12 months preceding randomization.\n\n         10. History of hypersensitivity to any beta2-agonist, sympathomimetic drug, inhaled\n             corticosteroids, or systemic corticosteroid therapy or any component of the possible\n             study treatments in this trial, including severe milk protein hypersensitivity.\n\n         11. Use of anti-IgE (e.g., omalizumab) or any other monoclonal antibody, in the 6 months\n             prior to randomization.\n\n         12. Use of (Beta) \u03b2-blockers within 1 day prior to first dose of study medication.\n\n         13. Use of ICS, LABA, ICS+LABA, LTRAs, leukotriene modifiers, anticholinergics, or\n             theophylline must be discontinued prior to the first dose of investigational\n             treatment.\n\n         14. Use of a potent CYP3A4 inhibitor within 4 weeks of randomization (e.g., ritonavir,\n             atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir,\n             saquinavir, ketoconazole, telithromycin)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "11700", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01845025", 
            "org_study_id": "CFOR258D2416"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Formoterol + fluticasone propionate 100 mcg", 
                    "Formoterol + fluticasone propionate 250 mcg", 
                    "Formoterol + fluticasone propionate 500 mcg"
                ], 
                "description": "Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler", 
                "intervention_name": "Formoterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Formoterol + fluticasone propionate 100 mcg", 
                "description": "Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler", 
                "intervention_name": "Fluticasone propionate 100 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Formoterol + fluticasone propionate 250 mcg", 
                "description": "Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler", 
                "intervention_name": "Fluticasone propionate 250 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Formoterol + fluticasone propionate 500 mcg", 
                "description": "Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler", 
                "intervention_name": "Fluticasone propionate 500 mcg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Fluticasone propionate 100 mcg", 
                    "Fluticasone propionate 250 mcg", 
                    "Fluticasone propionate 500 mcg"
                ], 
                "description": "Placebo to formoterol one inhalation twice daily via dry powder inhaler", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Formoterol", 
                "Fluticasone"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Asthma, formoterol fumarate, Foradil, inhaled corticosteroid, fluticasone propionate, safety", 
            "Asthma", 
            "formoterol fumarate", 
            "Foradil", 
            "inhaled corticosteroid", 
            "fluticasone propionate", 
            "safety"
        ], 
        "lastchanged_date": "March 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Avondale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "853253"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cave Creek", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85331"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85308"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Phoenix", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85051"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85254"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40218"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40207"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40214"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40243"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40220"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cordova", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38018"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38122"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38118"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38116"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Memphis", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "38104"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brookfield", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53005"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mequon", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53092"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53202"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S Milwaukee", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53172"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Waukesha", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53189"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Chrsitopher Compton", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Combined number of asthma-related hospitalization, asthma-related intubation, and asthma-related death.", 
            "measure": "Combined serious asthma related events", 
            "safety_issue": "Yes", 
            "time_frame": "26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01845025"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of asthma-related hospitalizations.", 
                "measure": "Asthma-related hospitalization", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Number of asthma-related intubation events", 
                "measure": "Asthma-related intubation", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Number of asthma-related deaths", 
                "measure": "Asthma-related deaths", 
                "safety_issue": "Yes", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Frequency of rescue medication use during study period", 
                "measure": "Rescue medication use", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Number of symptom and rescue-free days per patient", 
                "measure": "Symptom and rescue-free days", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Number of nighttime awakenings per patient", 
                "measure": "Nighttime awakenings", 
                "safety_issue": "No", 
                "time_frame": "26 weeks"
            }, 
            {
                "description": "Change in Asthma control Questionnaire (ACQ - 6) score from baseline", 
                "measure": "Asthma control Questionnaire (ACQ - 6) score", 
                "safety_issue": "No", 
                "time_frame": "baseline and 26 weks"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}